My post was intended to be a general FYI/caution to folks reading.
Though I agree that different hospitals may have different tests.
Yeah, that was part of my point.
You state
the UDS is targeted at looking for monoacetylmorphine, so only drugs undergoing this particular flavor of metabolism can be detected. Synthetics like fentanyl, demerol, or methadone won't trip a positive.
I quoted your post, but I was referring to that and just general FYI to people posting that "urine drug screens don't test for x, y, z"
This part of my point
So what the lab at your institution tests for
was that "urine drug screens" are essentially a panel that can have all kinds of things on them. Obviously with a cartridge or dipstick set up, you're limited to what's available on that, but if you're running them on a chemistry analyzer like bigger places often do you can essentially include whatever you want. If there's something providers want and aren't getting that would be helpful, you can probably get it. Our institution offers several "urine drug screens" we've got one for the ED, one for the pain clinic, etc. So the point I was attempting to make with that for the general audience of the forum was to be careful generalizing that what's on a screen at one place is the same at another, or that a provider can't request expanded options if needed. So saying a urine drug screen won't pick up fentanyl isn't necessarily true. Methadone also seems to be getting more popular for instance.
With respect to the "opiate" assay in particular...
If you have a UDS that will pick up oxy or the synthetics, then that's because your hospital has purchased either a stand-alone assay for that particular opioid or a more expensive UDS cartridge that includes them.
What is considered the "opiate" screen is an immunoassay targeted at morphine metabolites; and my original post stands.
-d
While these immunoassays are targeted at morphine metabolites as you've said, they cross react like crazy with other substances (most major reagent manufacturers list a couple dozen).
My intended caution was: which of these substances and the concentration thresholds of these other substances needed to trip the opiate screen positive varies greatly by reagent manufacturer because they each develop their own antibodies (proprietary issues and all that). Which is why I stated that people (in general, not just you specifically) need to be careful not to generalize that just because x metabolite, or semi-synthetic did or did not show up on the "opiate" part of the screen, that it's the same elsewhere. In that case I'm not referring to any instance of add-on options to a regular opiate immunoassay.
For instance you state that if" your screen picks up Oxy" it must be because there's either a standalone assay or more expensive cartridge being used. That's definitely NOT true. Pretty much all the regular opiate assays will pick up oxy at a certain concentration threshold (one that can realistically be seen in people in real life).
For example, our regular old basic opiate assay (single reagent, no upgrades/add-ons) from our toxicology lab targeted at morphine metabolites picks up Oxy no problem at levels you can reasonably expect to see in people (although you definitely wouldn't want to use it to screen specifically for oxy). However, in our core lab, the analyzer will give a negative for those same samples. We did a 48 patient sample comparison between the two labs and 13 samples gave discordant neg/pos results between the two labs. Tox lab's GC/MS confirmatory testing was done to find out the cross-reactivities responsible for the discrepancies. 5 of the discrepancies were due to oxy, the others were due to hydrocodone and hydromorphone. This wasn't unexpected.
Hence why I just wanted to point out to everyone that these assays all behave very differently from each other and care is needed when making conclusions about results from them.
The moral being that if someone is used to never seeing oxy trip a postive on an opiate screen then goes to moonlight at a place with an analyzer like our tox lab where it will test positive often, they might mistakenly determine that a patient on oxy who trips a positive must also be on something additional and they could be wrong.
So the laboratory operations management team I'm on got to spend quite a bit of time with the 10 or so laboratory directors for our health system sites having discussions how we were going to make providers aware of these differences when we shifted the ED drug screen from the tox lab to the core lab. Then more discussions with the ED folks on whether or not the performance of the assay was going to meet their needs.